← All trials
NCT04319757
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 18, 2020
- Primary completion
- Dec 31, 2021
- Completion date
- Jun 30, 2022
- First posted
- Mar 24, 2020
- Last posted
- Mar 24, 2020
- Enrollment
- 24
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Acepodia Biotech Inc.Lead sponsor
- Acepodia Biotech Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.